Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 227,700 shares, a drop of 26.8% from the August 31st total of 311,200 shares. Approximately 5.3% of the company’s shares are short sold. Based on an average trading volume of 9,700,000 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 9,700,000 shares, the short-interest ratio is currently 0.0 days. Approximately 5.3% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on APM shares. Wall Street Zen raised shares of Aptorum Group to a “sell” rating in a research report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aptorum Group in a research report on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Aptorum Group Price Performance

Shares of NASDAQ APM opened at $2.41 on Thursday. Aptorum Group has a 1 year low of $0.46 and a 1 year high of $7.49. The firm has a 50-day moving average of $1.85 and a 200 day moving average of $1.31.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.